ROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PD ...

Milestone advances manufacturing readiness and supports long-term commercialization strategyBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. The extended shelf life is validated by ongoing stabi ...

NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. “2025 has been a defining year for AtaiBeckley, marked by meaningful ...

MINNEAPOLIS, Dec. 23, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 2026 J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 9:00 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences ...

SINGAPORE, Dec. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) “EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration of its longevity and regenerative medicine strategy with the launch of a comprehensive stem cell therapy platform and establishment of its first clinic in Shenzhen, China. This strategic advancement builds on the Company’s earlier acquisition of distrib ...

公司核心业务与研发管线 - Atea Pharmaceuticals (AVIR) 正在开发针对丙型肝炎病毒(HCV)和戊型肝炎病毒(HEV)的抗病毒疗法 [1] - 其主导候选药物是bemnifosbuvir/ruzasvir (BEM/RZR)，旨在实现HCV的治愈，目前正在两项平行的3期临床试验中进行评估，其中一项在北美进行 [1] 文章作者背景与立场 - 文章作者是一名参与临床研究的医生，投资风格专注于临床阶段生物技术股票，仅做多，包括长期投资和事件驱动交易 [1] - 其学术和医学背景有助于评估生物技术股票的科学基本面 [1] - 作者声明在AVIR股票中拥有多头仓位，可能通过股票所有权、期权或其他衍生品实现 [2]

公司业务与产品管线 - Atea Pharmaceuticals (AVIR) 正在开发针对丙型肝炎病毒(HCV)和戊型肝炎病毒(HEV)的抗病毒疗法 [1] - 其主导候选药物是bemnifosbuvir/ruzasvir (BEM/RZR)，旨在实现HCV的治愈，目前正在两项平行的3期临床试验中进行评估，其中一项在北美进行 [1] 作者背景与立场 - 文章作者是一名参与临床研究的医生，投资风格专注于临床阶段生物技术股票，仅做多，包括长期投资和事件驱动交易 [1] - 其学术和医学背景有助于评估生物技术股票的科学基本面 [1] - 作者声明在AVIR股票中拥有多头权益，可能通过股票、期权或其他衍生品持有 [2] - 文章表达作者个人观点，且除Seeking Alpha外未因本文获得其他报酬 [2]

文章核心观点 - 生物科技股通常由数据驱动 但股价并不总能完全反映数据所隐含的价值 CG Oncology Inc (CGON) 的情况便是如此 其股价表现与公司发布的数据所暗示的价值存在脱节 [1] 公司数据与市场反应 - 自首次公开募股以来 CG Oncology Inc (CGON) 发布的数据所隐含的价值与其股价表现之间存在脱节 [1]

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%) Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, two key and central drivers of type 2 ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function compared to placebo (by 4.68% to 5.32%)    Dupixent is the first and only biologic medicine to demonstrate improved lung function in this young patient group in a randomized phase 3 study, and inhibits IL-4 and IL-13, two key and central drivers of type ...